Arteris and Everspin Technologies both operate in the semiconductor ecosystem, but they serve different layers of the technology stack. Arteris supplies network-on-chip (NoC) interconnect intellectual property (IP) that helps engineers connect components inside complex AI and chiplet-based processors, while Everspin designs and manufactures magnetoresistive random-access memory (MRAM), a non-volatile memory used in industrial, medical, aerospace, and data-center systems. Both names have delivered strong revenue growth in recent quarters and both have pulled back sharply from earlier 52-week highs, making this stock comparison timely for investors weighing AI-driven design growth against a specialized, hardware-centric memory business. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Arteris, Inc. is a Campbell, California-based provider of semiconductor interconnect IP and design tools. Its network-on-chip technology coordinates on-chip data movement in increasingly complex processors, a role that has gained relevance as AI accelerators and multi-die "chiplet" designs multiply. In its most recent quarter, Arteris reported revenue of $25.8 million, up 48% year over year, with a narrowed non-GAAP operating loss and raised full-year revenue guidance. Management cited record contracted backlog — including remaining performance obligations above $135 million — and the milestone of surpassing 1,000 customer design starts. Despite strong fundamentals, the stock has retreated substantially from its 52-week high, reflecting profit-taking and valuation concerns around a company that remains loss-making on a GAAP basis. Recent weeks have shown consolidation in the high-teens price range. From what I see, the AI tailwinds here remain worth monitoring closely.
Everspin Technologies is the world's leading commercial developer of MRAM, a persistent memory that retains data without power, which suits mission-critical applications. Headquartered in Chandler, Arizona, the company operates a fabrication facility and sells into industrial automation, data center, medical, automotive, and aerospace markets. In its latest quarter, Everspin posted record revenue of $20.6 million, up 47% year over year, with non-GAAP net income of $0.12 per share and gross margin above 50%. Growth was driven by industrial automation recovery, data-center demand, and a $40 million subcontract with a U.S. prime contractor, alongside a foundry agreement with Microchip and a partnership with Teledyne HiRel. However, litigation and regulatory costs — including a provision tied to export-control matters — continue to weigh on GAAP results, and the company filed a $100 million mixed shelf offering in recent weeks. The stock has experienced notable volatility, trading well below its 52-week high.
The clearest contrast between these two stocks lies in their business models. Arteris is an asset-light IP licensing and royalty business with an 87% gross margin and a recurring royalty stream that is still ramping, positioning it as a high-multiple, growth-oriented play on AI and chiplet adoption. Everspin is a capital-intensive chip manufacturer whose economics depend on fabrication capacity, product mix, and manufacturing costs, with gross margins above 50% and non-GAAP profitability already in place. On growth drivers, Arteris leans on design wins converting into future royalties, while Everspin leans on near-term shipments and government-linked contracts. Risk profiles also differ: Arteris faces dilution from stock-based compensation and GAAP losses, while Everspin contends with litigation, regulatory fines, a shelf offering, and a beta near 2.1, indicating higher market sensitivity. On market sentiment, both stocks have cooled after speculative run-ups, but Arteris retains a larger market capitalization and a steadier trend following its earnings beat-and-raise. I checked comparable names in the space using Tickeron’s AI Screener for additional perspective.
Based on observable factors, Tickeron's AI would likely favor AIP over MRAM in the current environment. Arteris combines a debt-free balance sheet, a record contracted backlog, raised guidance, and a clear, recurring royalty catalyst tied to AI and chiplet designs — factors that support more consistent trend behavior and relative positioning. Everspin's momentum and non-GAAP profitability are notable, but its higher volatility, litigation and regulatory overhangs, and capital-intensive model introduce greater uncertainty. This assessment reflects a probabilistic reading of current data rather than a definitive forecast, and conditions can shift as new earnings and market data emerge. In my view, the stability edge for Arteris stands out here.
I often turn to Tickeron’s tools when comparing names like these, and the Trending AI Robots section stands out as a practical resource. It curates a focused set of AI trading bots suited to current conditions across different styles and timeframes, helping narrow options without sifting through the full library. This has been a useful step in my own process for identifying relevant automated strategies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MRAM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 38 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 83%.
The 50-day moving average for MRAM moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for MRAM entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRAM's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on MRAM as a result. In 61 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +20.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRAM advanced for three days, in 222 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
MRAM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.910) is normal, around the industry mean (5.443). P/E Ratio (-97.833) is within average values for comparable stocks, (15.640). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.803). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. P/S Ratio (5.328) is also within normal values, averaging (46.468).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MRAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of magnetic random access memory chips
Industry Semiconductors